A development of LC–MS method combining ultrafiltration and lyophilization for determination of r-RGD-Hirudin in human serum

Su, Shengmin; Yu, Yunqiu; Mo, Wei; Zhang, Yanling; Song, Houyan; Chen, Qin-Fen; Xie, Yi

doi:10.1016/j.jchromb.2008.05.032

Cited by 8 publications

(3 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma was obtained by centrifuging at 4500 rpm for 10–15 min and transferred to a fresh tube; aPTT, PT, and TT were measured using a full-automatic blood coagulation apparatus (Sysmex CA-1500, Japan). Liquid chromatography-mass spectrometry (LC-MS, Agilent G1946D Quadrupole Plain Detector) was also conducted to directly detect the change in concentration of r-hirudin in rats serum for bioavailability analysis based on previously established methods [43] .…”

Section: Methodsmentioning

confidence: 99%

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease

Xia

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease

Xia

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Blood samples were collected before treatment and 0-7 h after treatment from the carotid artery. Liquid chromatography-mass spectrometry (LC-MS, Agilent G1946D Quadrupole Plain Detector) was also conducted to directly detect the change in concentration of PTIP in rats serum for bioavailability analysis based on previously established methods 29 .…”

Section: Bioavailability Analysismentioning

confidence: 99%

“…Liquid chromatography-mass spectrometry (LC-MS; Agilent G1946D Quadrupole Plain Detector) was also conducted to directly detect the change in concentration of PTIP in rats' serum for bioavailability analysis based on previously established methods. 29 Ferric Chloride Injury Model SD rats (300 AE 30 g, male, n ¼ 6 per group) were injected with saline, eptifibatide (180 µg/kg, iv), bivalirudin (1 mg/kg, iv), eptifibatide (180 µg/kg, iv) þ bivalirudin (1 mg/kg, iv), DTIP (1 mg/kg, iv), and PTIP (1 mg/kg, iv and sc). After 0.5 hour, recipient mice were anesthetized with sodium pentobarbital followed by surgical exposure of the carotid artery or jugular vein.…”

Section: Bioavailability Analysismentioning

confidence: 99%

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

Yu,

Wang,

Zhang

et al. 2023

Thromb Haemost

Self Cite

View full text Add to dashboard Cite

Classical anticoagulants and antiplatelets are associated with high frequencies of bleeding complications or treatment failure when used as single agents. Thrombin plays an important role in the blood coagulation system. GP IIb/IIIa is the central receptor of platelets, which can recognize the Arg-Gly-Asp (RGD) sequence and activate platelets. We have constructed a novel dual-target peptide (PTIP) based on the direct thrombin inhibitor peptide (DTIP) via molecular simulation and homology modeling. PTIP was expressed at high levels in Pichia pastoris. PTIP interfered with thrombin-mediated coagulation and ADP-induced platelet aggregation in vitro. When injected intravenously or subcutaneously, PTIP showed potent and dose-dependent extension of aPTT and PT which were similar to DTIP; but only PTIP was capable of inhibiting platelet aggregation. The antithrombotic activity of PTIP was determined by ferric chloride injury model, pulmonary thromboembolism model, and arteriovenous bypass thrombosis model. PTIP (1.0 mg/kg) decelerated thrombosis formation in venous and arterial vessels induced by FeCl3 injury. PTIP (1.0 mg/kg) also prevented deep venous thrombosis and increased the survival rate associated with pulmonary thromboembolism. And PTIP effectively reduced thrombus length in arteriovenous bypass thrombosis model. Moreover, the antithrombotic dose of PTIP could not induce bleeding determined by transecting distal tail assay. These data establish that PTIP represents a novel antithrombotic agent whose effects involve both inhibition of platelet activation and reduction of fibrin generation. And PTIP not only can be used in venous thrombosis and arterial thrombosis, it can also replace the combined treatment of antiplatelet and anticoagulant drugs in thrombotic diseases.

show abstract

Sample Preparation for LC‐MS Bioanalysis of Peptides

Yuan¹

2019

Sample Preparation in LC‐MS Bioanalysis

View full text Add to dashboard Cite

A development of LC–MS method combining ultrafiltration and lyophilization for determination of r-RGD-Hirudin in human serum

Cited by 8 publications

References 13 publications

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

Sample Preparation for LC‐MS Bioanalysis of Peptides

Contact Info

Product

Resources

About